Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05425745
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:42.630443+00:00
Published At
2025-06-11T00:00:00+00:00
Record Updated At
2025-06-11
Results Posted At
2025-06-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Dyslipidemias", "High Cholesterol", "Hypercholesterolemia", "Familial Hypercholesterolemia", "Lipid Metabolism Disorder", "Metabolic Disease", "Lipid Metabolism, Inborn Errors", "Genetic Disease, Inborn", "Hyperlipoproteinemias"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-11"
protocolSection.identificationModule.nctId
"NCT05425745"
protocolSection.identificationModule.officialTitle
"A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-06-11"

Study condition terms

  • Dyslipidemias (protocolSection.conditionsModule.conditions)
  • High Cholesterol (protocolSection.conditionsModule.conditions)
  • Hypercholesterolemia (protocolSection.conditionsModule.conditions)
  • Familial Hypercholesterolemia (protocolSection.conditionsModule.conditions)
  • Lipid Metabolism Disorder (protocolSection.conditionsModule.conditions)
  • Metabolic Disease (protocolSection.conditionsModule.conditions)
  • Lipid Metabolism, Inborn Errors (protocolSection.conditionsModule.conditions)
  • Genetic Disease, Inborn (protocolSection.conditionsModule.conditions)
  • Hyperlipoproteinemias (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.